A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors
Clinical trial NCT01068977 · COMPLETED
Trial details
- NCT number
- NCT01068977
- Sponsor
- Genentech, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2007-08-01
- Primary completion
- 2010-01-01
- Enrollment
- 44
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.